Dr. Reddy's Laboratories (NYSE:RDY) enters into a license agreement with Eisai (OTC:ESALF)(OTCPK:ESALY) for exclusive worldwide (except Japan and Asia) development and commercialization rights to investigational cancer agent E7777, including India.
Under the terms of the deal, Eisai will receive unspecified regulatory and sales-based milestones.
E777 is a fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments. It binds to IL-2 on the cancer cell surface enabling diphtheria toxins to enter the cell and inhibit protein synthesis. A Phase 2 study in cutaneous T-cell lymphoma or peripheral T-cell lymphoma is underway in Japan. A Phase 3 study in cutaneous T-cell lymphoma is being readied in the U.S.
Subscribe for full text news in your inbox